🇺🇸

US SEC Filing Intelligence

· daily

HHS & Healthcare Contracts Intelligence — June 23, 2026

The June 23, 2026 HHS contracts digest totals $262.8 million in obligations, split entirely between two civilian-sector awards from HHS agencies (BARDA and NIH/NCI). The largest contract is a $141.3 million biotechnology R&D award to START2 GROUP, INC., an early-stage small disadvantaged business, raising execution risk given only $2.8 million outlayed to date. Leidos Biomedical Research’s $121.5 million cost-plus-fixed-fee award provides stable, low-risk revenue through August 2024, but with modest profit upside. The dominant sector theme is sustained federal health R&D investment, though both contracts exhibit neutral signals with no clear bullish catalysts, while START2 GROUP’s performance milestone risk is a key watch item for investors tracking small-cap government services exposure.

2 total filings
· daily

New Federal Contractors — June 23, 2026

The three contracts awarded between June 23, 2026, and June 23, 2026, total $401.1 million, with one-third defense-related and an average signal strength of 5.7/10. The dominant theme is civilian health and security spending, led by HHS ($262.8M combined across START2 GROUP and Leidos Biomedical) and DHS/TSA ($138.3M to Analogic Corp). Highest-conviction signal is the bullish, competitive win by Analogic Corp for $138.3M in TSA CT systems, offering long-term revenue visibility through 2033. Key risk is execution and scalability for START2 GROUP, a small, foreign-owned disadvantaged business with only $2.8M outlayed on a $141.3M BARDA contract, presenting high pricing risk and early-stage funding gaps.

3 total filings
· daily

Significant Contract Modifications ($10M+) — June 23, 2026

The three contracts analyzed total $401.1 million in obligations, with a civilian-heavy split (2/3 HHS, 1/3 DHS) and no direct DoD awards. The dominant theme is federal investment in advanced health R&D and airport security technology, with BARDA (HHS) and TSA (DHS) as key agencies. The highest-conviction signal is the bullish $138.3 million TSA CT system award to Analogic Corp, reflecting competitive strength and long-term revenue visibility through 2033. Key risks include the early-stage, high-execution-risk $141.3 million BARDA contract to START2 GROUP, INC., which has only $2.8 million outlayed, and the upcoming August 2024 expiration of Leidos Biomedical Research's $121.5 million NIH contract, which creates re-compete uncertainty.

3 total filings
· daily

Contract Deobligations Alert — June 23, 2026

This digest covers $401.1 million in total obligations across three contracts, with a 2:1 civilian-to-defense split (HHS and DHS vs. no pure DOD awards). The highest-conviction signal is Analogic Corp's $138.3 million TSA CT system delivery order, a competitive win in a growing airport security market with $499.7 million in potential value through 2033. The largest contract, START2 GROUP's $141.3 million BARDA biotechnology R&D award, carries high execution risk due to only $2.8 million outlayed and the company's small, foreign-owned status. A key risk is the upcoming August 2024 expiration of Leidos Biomedical Research's $121.5 million NIH contract, which may signal a re-compete or budget shift for NIAID vaccine research.

3 total filings
· daily

Contract Option Exercises — June 23, 2026

The three contracts totaling $401.1 million are heavily skewed toward civilian agencies (HHS and DHS), with only one-third defense-related, reflecting continued federal investment in health security and advanced airport screening technology. The highest-conviction signal is Analogic Corp's $138.3 million TSA delivery order for CT systems, a competitive win with a potential $499.7 billion ceiling that underscores durable demand for aviation security upgrades. Key risks include execution uncertainty on START2 Group's early-stage $141.3 million BARDA contract (only $2.8 million outlayed) and the pending August 2024 renewal of Leidos' $121.5 million NIH contract. Investors should monitor TSA budget cycles for Analogic's option exercises and START2 Group's milestone progress as critical catalysts.

3 total filings
· daily

All HHS Contracts — June 23, 2026

This digest covers two HHS contracts totaling $262.8 million, both civilian (non-defense) awards, with a dominant theme of federal health R&D spending. The highest-conviction signal is Leidos Biomedical Research’s $121.5 million cost-plus-fixed-fee delivery order from NIH/NCI, which provides stable, predictable margins through August 2024 but caps upside. The more speculative signal is START2 GROUP’s $141.3 million BARDA contract, which carries high execution risk due to only $2.8 million outlayed to date and the company’s small, foreign-owned status. Key risk: START2’s contract is early-stage and milestone-dependent, with potential for delays or protest vulnerability. Key watch item: Leidos’ contract renewal or follow-on award after August 2024, which will signal NIH budget continuity for vaccine research.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 23, 2026

The three contracts totaling $401.1 million are overwhelmingly civilian, with two HHS awards and one DHS award; only the TSA contract for Analogic Corp carries a defense-adjacent security mission. The highest-conviction signal is Analogic Corp's $138.3 million delivery order for full-sized CT systems, which provides long-term revenue visibility through 2033 and reflects competitive strength in airport security technology. The largest contract by value, START2 GROUP, INC.'s $141.3 million BARDA award, carries high execution risk due to minimal outlays ($2.8M) and a small, foreign-owned contractor profile. A key risk is the impending expiration of Leidos Biomedical Research's $121.5 million NIH contract in August 2024, which creates a re-compete event that could affect Leidos' health R&D revenue stream.

3 total filings
· daily

High-Value Federal Grants ($5M+) — June 23, 2026

This digest covers $401.1 million in high-value federal obligations from June 23, 2026, with a 1:2 defense-to-civilian split. The dominant theme is advanced technology procurement for health/biodefense (HHS/BARDA and NIH) and homeland security (TSA). The highest-conviction signal is Analogic Corp's $138.3 million TSA CT system delivery order, which provides long-term revenue visibility through 2033 and signals competitive strength in airport security detection. A key risk is the START2 GROUP, INC. $141.3 million BARDA contract, where only $2.8 million has been outlayed, indicating early-stage execution risk and potential scalability concerns for a small, foreign-owned firm.

3 total filings
· daily

General Federal Contracts — June 23, 2026

The three contracts analyzed total $401.1 million in obligations, with a civilian-heavy split (2 of 3 from HHS, 1 from DHS) and no direct defense awards, though the DHS TSA contract supports national security infrastructure. The dominant sector theme is health and biodefense R&D, driven by BARDA and NIH funding, with a secondary theme in advanced airport security technology via TSA. The highest-conviction signal is the bullish $138.3 million Analogic Corp TSA CT systems delivery order, which offers long-term revenue visibility through 2033 and reflects competitive strength in a high-value security niche. A key risk is the $141.3 million START2 GROUP contract with BARDA, where only $2.8 million has been outlayed, signaling early-stage execution risk and potential milestone delays.

3 total filings
· daily

S&P 500 Technology Sector SEC Filings — June 23, 2026

The 22 filings from S&P 500 Technology constituents on June 23, 2026, reveal a sector defined by massive capital returns, significant insider profit-taking, and a governance overhang at Snowflake. Accenture's $7.5B buyback program and IBM's credit facility extension signal robust balance sheet strength and shareholder return commitments. However, a wave of insider selling, particularly the $119M sale by NVIDIA Director Mark Stevens and substantial sales by CrowdStrike's top executives, introduces a cautionary note, suggesting insiders are locking in gains amid elevated valuations. The period-over-period data, while not directly present in these specific filings, is reflected through the scale of capital deployment and insider actions. The key themes are capital allocation confidence versus insider valuation concerns, with Snowflake's proxy fight representing a distinct corporate governance risk. Investors should monitor these patterns for potential divergence between management actions and market sentiment.

20 high priority 2 medium 22 total filings
· daily

Nasdaq 100 Stocks SEC Filings — June 23, 2026

The six filings for June 23, 2026, all relate to NVIDIA Corporation, a core NASDAQ-100 constituent. The dominant theme is a coordinated wave of insider transactions, with five top executives (including CEO Jensen Huang and CFO Colette Kress) executing tax-withholding share disposals totaling ~$40.3M at $207.41, while Director Mark Stevens executed a large open-market sale of ~$119M at $210.44. This pattern of insider liquidity events, particularly the CEO's first significant disposal in months, creates a nuanced signal: the tax-withholding sales are routine, but Stevens' sale is a material bearish indicator. No period-over-period comparisons, forward-looking guidance, or capital allocation data were present in these filings, limiting trend analysis. The key takeaway is elevated insider selling pressure at a high stock price, warranting close monitoring for any follow-on sales or changes in corporate outlook.

6 high priority 6 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — June 23, 2026

This batch of 43 filings reveals a concentrated period of activist and institutional activity on June 23, 2026, with several high-conviction themes emerging. A significant activist campaign is underway at **Equus Total Return (EQS)**, where a 5.6% holder publicly excoriated the board for a 65% NAV decline and excessive pay, demanding a strategic review. Concurrently, we see major insider monetization events: the CEO of **AST SpaceMobile** entered a $146.7M prepaid forward, and the CEO of **St. Joe Co** sold 622,200 shares. On the M&A front, **Apogee Therapeutics** agreed to a $135.11/share buyout by AbbVie, with activist holder Fairmount committing to support the deal. A notable pattern of institutional exit filings emerged, with **CDT Equity**, **CoreWeave**, and **Arqit Quantum** all seeing major holders reduce or eliminate stakes. The data also highlights a cluster of passive institutional positions in **Sleep Number Corp**, with both Jane Street and AQR Capital disclosing stakes exceeding 5%, suggesting a potential value play in the beaten-down retail sector. Overall, the filings paint a picture of significant capital rotation, with activists targeting underperformers for change and institutions adjusting positions ahead of a potential market inflection.

18 high priority 25 medium 43 total filings
· daily

S&P 500 Financials Sector SEC Filings — June 23, 2026

The five filings from S&P 500 Financials constituents reveal mixed insider sentiment with notable selling from AFLAC’s largest holder and Progressive’s CIO, while Mastercard’s director transaction is neutral. The sole operational filing is a Wells Fargo CMBS trust 8-K announcing a $475M multi-family/commercial mortgage securitization, signaling ongoing capital markets activity. No period-over-period comparisons or financial metrics are available from these filings, limiting trend analysis. Insider selling patterns in insurance (AFLAC, Progressive) warrant monitoring, but most trades are 10b5-1 pre-arranged. The CMBS issuance points to continued structured credit demand, potentially benefiting large banks. Overall, the filings suggest caution in insurance names and a steady but not explosive securitization environment.

4 high priority 1 medium 5 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — June 23, 2026

The sole filing from Conagra Brands within the Consumer Staples stream for this period is a routine, low-materiality 8-K regarding a director's decision not to stand for reelection. The departure of Emanuel 'Manny' Chirico is explicitly stated as not due to any disagreement, which removes a typical governance risk. The filing provides no period-over-period financial data, insider trading activity, capital allocation updates, or forward-looking guidance. Consequently, the digest is dominated by a single, neutral governance event. The primary actionable insight is the scheduled September 2026 Annual Meeting, which serves as a key date to monitor for any strategic shifts or further board changes. The lack of financial or operational data from this filing prevents any sector-wide trend analysis or comparison against other Consumer Staples peers.

1 high priority 1 total filings
· daily

S&P 500 Industrials Sector SEC Filings — June 23, 2026

This quiet session features only one filing from FedEx Corp., a transportation heavyweight in the S&P 500 Industrials. The standout development is the completion of the FedEx Freight spin-off on June 1, 2026, a transformative corporate action that unlocks significant value while loading FedEx Freight with $3.7B in debt. FedEx’s FY2026 results show strong top-line momentum (revenue up 12.6% YoY for Q4, 7.7% for the full year), but margin compression persists—GAAP operating margin fell 190 bps YoY in Q4, signaling cost pressures from the spin-off and elevated investments. Capital spending dropped to a record-low 4.0% of revenue, reflecting capital discipline, but insider selling by a key executive raises caution. Forward guidance points to ~11% revenue growth in calendar 2026, but adjusted EPS estimates ($16.90-$18.10) imply a tepid profit recovery. The key portfolio-level takeaway: Industrial companies are aggressively restructuring (spin-offs, cost-cutting) but facing headwinds in margin expansion.

1 medium 1 total filings
· daily

S&P 500 Energy Sector SEC Filings — June 23, 2026

The single filing from ConocoPhillips today (an 8-K) is a low-materiality personnel announcement, providing no financial data for period-over-period comparisons, insider transactions, or forward-looking guidance. The retirement of General Counsel Kelly B. Rose, effective September 1, 2026, is a routine succession event with no immediate market impact. Without revenue, margin, or capital allocation data from this filing, no sector-wide themes or portfolio-level trends can be derived. The digest is therefore limited to a single governance-related watch item. No other S&P 500 Energy constituents filed today, resulting in an absence of actionable investment signals, risk flags, or opportunities from this batch.

1 high priority 1 total filings
· daily

US Material Events SEC 8-K Filings — June 23, 2026

This batch of 50 filings reveals a market bifurcated between aggressive capital-raising activities and strategic refinancing, with a notable undercurrent of insider transitions. The most critical developments include a massive $650 million crypto-linked offering from CIMG Inc. that poses extreme dilution risk, and a $200 million dilutive equity raise by AMC Entertainment to address near-term debt maturities. Conversely, several companies are strengthening balance sheets through asset sales (FMC Corp's $114M property sale) and credit facility expansions (PG&E's $850M increase, IFF's $1.5B term loan). The M&A landscape shows a significant tax-free merger in the private credit space (Manulife/John Hancock Comvest) and a high-value biotech licensing deal (Nuvectis Pharma with up to $1.46B in milestones). Leadership changes are widespread, with 10+ filings involving C-suite or board appointments, including a notable CFO transition at NIKE from Pfizer. Period-over-period data from Worthington Enterprises shows strong revenue growth (17% YoY) but mixed profitability, while Ashford Hospitality's asset sale improves its loss profile but leaves it with negative equity. The overall sentiment is cautiously neutral, with pockets of high risk from dilutive financings and accounting restatements.

50 high priority 50 total filings
· daily

Insider Trading Pulse — June 23, 2026

The June 23, 2026 insider trading digest reveals a market dominated by routine, non-directional transactions (tax-withholding share settlements, equity awards, and 10b5-1 plan sales), masking a few high-conviction signals. The most critical development is the massive $14M sale by SharkNinja's CEO under a 10b5-1 plan, the largest single insider disposition of the day, which warrants close monitoring for future insider activity. A notable cluster of negative sentiment emerges from Sea Ltd, where both the CFO and COO executed pre-planned sales totaling ~$1.3M, while a positive outlier is the $1.95M open-market purchase by a 10% owner in USVC Venture Capital Access Fund, signaling strong conviction in the venture capital space. Period-over-period trends are limited in this filing set, but the prevalence of 10b5-1 sales (Sea Ltd, SharkNinja, Crescent Biopharma, 4D Molecular Therapeutics) suggests that many insiders are pre-committing to liquidity events, which is a neutral signal. The data set is heavily weighted toward neutral events (tax withholdings, awards, gifts), with only a handful of actionable buy/sell signals, making the few directional trades—particularly the AST SpaceMobile CEO's forward contract obligation to sell—the most important items for investors to analyze.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — June 23, 2026

The 8 filings from Dow 30 constituents on June 23, 2026, reveal a mixed picture of financial stability and management transitions. IBM's proactive extension of its $2.5B credit facility through 2029 signals strong liquidity management and lender confidence, a positive for balance sheet strength. NIKE's CFO transition from Pfizer's David Denton is a key leadership change, coupled with a one-time tariff refund benefit that will boost Q4 FY2026 results, though core performance remains in line with guidance. The six Salesforce filings show a pattern of routine insider stock transactions—primarily tax withholding upon vesting—by top executives, which is neutral and reflects normal compensation cycles rather than directional conviction. No period-over-period comparisons, forward-looking guidance, or capital allocation changes were present in these filings, limiting trend analysis. The overall theme is one of corporate stability with minor operational adjustments, offering no major bullish or bearish catalysts but highlighting IBM's financial prudence and NIKE's strategic leadership refresh.

8 high priority 8 total filings
· daily

US SEC Filings Daily Market Digest — June 23, 2026

Today's filings reveal a market bifurcated between aggressive capital deployment and defensive restructuring. A clear theme is the wave of SPAC and M&A activity, with Graf Global Corp. targeting a $290M merger with the BIG3 basketball league and multiple BDC mergers (Manulife Private Credit Fund, John Hancock Comvest Private Income Fund) signaling consolidation in the private credit space. On the capital allocation front, Robinhood Markets is executing a bold $2.0B zero-coupon convertible note offering, while Equinor and News Corp continue buyback programs, though Equinor's average repurchase price has declined 9.6% under the current tranche, indicating a falling share price. Mixed signals dominate: insider activity is sparse, but several companies (Tempest Therapeutics, Comscore) are seeking shareholder approval for dilutive equity issuances. Period-over-period data is limited in these filings, but Critical Metals Corp. showed a dramatic improvement in net loss (from A$200.3M to A$96.8M), driven by non-recurring items, while simultaneously seeing a 40x surge in share-based compensation, a red flag for governance. The most critical development is the upcoming special meeting season on July 30, 2026, where three XAI funds are seeking to replace sub-advisers, a move that could reshape their investment strategies and fee structures.

24 high priority 26 medium 50 total filings